Seoul, South Korea

Cenyx Biotech Inc.


USPTO Granted Patents = 5


Trademarks = 2

Forward Citations = 0

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Dong-Wan Kang (3 out of 3 patents)

silverMedal Bong Geun Cha (3 out of 3 patents)

bronzeMedal Seung-hoon Lee (3 out of 55 patents)

4.  Han-Gil Jeong (2 out of 4 patents)

5.  Jaeyun Kim (2 out of 3 patents)

6.  Do Yeon Kim (2 out of 66 patents)

7.  Sumin Lee (1 out of 23 patents)

8.  Seul Ki Ki (1 out of 1 patent)

9.  So Hyun Jeon (1 out of 1 patent)

10.  Ju Hee Han (1 out of 1 patent)


5 patents:

Company Overview
Cenyx Biotech Inc. is a pioneering biotechnology company focused on developing innovative solutions for healthcare challenges. With a commitment to advancing medical research, Cenyx specializes in the discovery and commercialization of novel therapeutics and diagnostics. The company leverages cutting-edge technologies and a team of experienced scientists to address unmet medical needs in various therapeutic areas, including oncology, infectious diseases, and rare genetic disorders. Cenyx Biotech aims to improve patient outcomes through its robust pipeline of products and collaborations with leading research institutions. By fostering a culture of innovation and excellence, Cenyx is dedicated to transforming the future of medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#671 in Seoul

#1,879 in South Korea

Seoul, KR
Seoul, South Korea
Forward Citations = 0

10 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cenyx Biotech Inc.. Retrieved from https://idiyas.com/company/cenyx-biotech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…